Castle Biosciences, Inc. $CSTL Shares Sold by UBS Group AG

UBS Group AG lessened its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 51.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 141,873 shares of the company’s stock after selling 149,489 shares during the quarter. UBS Group AG’s holdings in Castle Biosciences were worth $5,519,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Amundi raised its position in Castle Biosciences by 15,811.5% in the first quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after purchasing an additional 4,111 shares during the period. AQR Capital Management LLC boosted its position in shares of Castle Biosciences by 548.9% in the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after buying an additional 115,907 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after buying an additional 655 shares during the period. Jones Financial Companies Lllp grew its stake in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after buying an additional 2,648 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Castle Biosciences by 34.7% in the second quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock valued at $713,000 after buying an additional 8,992 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL opened at $20.03 on Thursday. The company has a quick ratio of 6.53, a current ratio of 6.75 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $44.28. The business has a 50 day moving average price of $23.69 and a two-hundred day moving average price of $31.85. The firm has a market cap of $607.51 million, a PE ratio of -45.52 and a beta of 1.11.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.49). The company had revenue of $84.23 million for the quarter, compared to analyst estimates of $79.23 million. Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%. Sell-side analysts expect that Castle Biosciences, Inc. will post -1.4 earnings per share for the current fiscal year.

Insider Activity at Castle Biosciences

In related news, insider Tobin W. Juvenal sold 20,863 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $25.24, for a total value of $526,582.12. Following the sale, the insider directly owned 86,825 shares of the company’s stock, valued at $2,191,463. This represents a 19.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director G Bradley Cole sold 7,403 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $28.47, for a total transaction of $210,763.41. Following the transaction, the director owned 19,309 shares in the company, valued at $549,727.23. This trade represents a 27.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 84,411 shares of company stock worth $2,166,211 in the last ninety days. 6.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on CSTL. Guggenheim boosted their price target on Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 27th. KeyCorp reiterated an “overweight” rating and set a $50.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 29th. Weiss Ratings cut shares of Castle Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, May 7th. Finally, BTIG Research decreased their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.33.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.